#United States #San Diego #biopharmaceuticals #Abzena #Mabqi

Strategic Partnership Overview

Abzena, renowned for being a top-tier integrated Contract Development and Manufacturing Organization (CDMO), and Mabqi, a pioneer in the biotechnology sector focused on human antibody development, have officially announced their partnership. This collaboration aims to revolutionize the way biopharmaceutical companies approach drug development by seamlessly integrating discovery with development solutions.

Significance of the Partnership

In today’s fast-paced biopharmaceutical landscape, early-stage development often poses significant challenges. Both Abzena and Mabqi recognize these hurdles and have joined forces to provide an end-to-end solution that covers every phase of drug development—from the initial discovery of antibody candidates to the advanced stages of pre-clinical development. This approach promises to enhance operational efficiencies, reduce timelines, and boost the overall success rate of drug development.

Enhanced Capabilities

The collaboration will combine Mabqi’s advanced antibody discovery expertise with Abzena's robust development and manufacturing services. Mabqi’s LiteMab Antibody Discovery Studio offers sophisticated tools for hit screening, candidate characterization, and selection, utilizing pH-sensitive libraries to identify promising leads. On the other hand, Abzena will contribute its extensive capabilities in developability, cell line development, and GMP manufacturing.

Both organizations possess a wealth of experience across a diverse range of modalities, including monoclonal antibodies (mAbs), multi-specific antibodies, and bioconjugates. This synergy is tailored to meet the complex needs of modern biopharma clients.

Insights from Leadership

Campbell Bunce, the Chief Scientific Officer at Abzena, expressed his enthusiasm regarding the partnership, stating, "Our collaboration with Mabqi melds two science-driven entities committed to pushing the frontiers of antibody innovation. This joint capability empowers our customers to expedite their development processes, using data-driven strategies to streamline operations and mitigate risks early in the development cycle."

Sylvain Yon, the CEO of Mabqi, echoed similar sentiments, regarding the partnership as a milestone for expanding integrated solutions in antibody development. He noted, "What distinguishes this collaboration is not just our complementary scientific strengths but also the exceptional chemistry between our teams, enabling a seamless cooperative spirit. This shared commitment to innovation allows us to focus intensely on the needs of our customers, paving the way for breakthrough therapeutic antibodies that have the potential to improve patient outcomes worldwide."

A Focus on Innovation and Customer Success

This partnership underscores both companies' dedication to bridging the gaps in biopharmaceutical development. By integrating their strengths, Abzena and Mabqi aim to provide an unprecedented level of comprehensive support to researchers and developers. This approach is designed not just to enhance the scientific rigor of drug development but also to create a customer-centric consultation process that anticipates and meets specific business needs.

As this strategic alliance unfolds, the biopharma industry can look forward to a more streamlined process that promises both speed and efficiency in bringing innovative treatments to market.

About Abzena

Abzena is a leading integrated CDMO and Contract Research Organization (CRO) specializing in bioconjugates and complex biologics. The company offers a comprehensive array of services that spans from early discovery to commercial launch, tailored to mitigate risks and enhance the development processes for new therapies.
Its robust infrastructure includes facilities in key locations such as San Diego, CA; Bristol, PA; and Cambridge, UK, all designed to support the specialized needs of biotech and biopharma industries. Abzena is under the ownership of Welsh, Carson, Anderson & Stowe, a prominent private equity firm known for its investment in health-related initiatives.

About Mabqi

Mabqi is a cutting-edge biotechnology firm that specializes in developing fully human antibodies aimed at advancing therapeutic modalities. Utilizing an innovative discovery platform, Mabqi employs strategies for developing monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and various immunotherapy formats that meet the demands of modern medicine.